Patent · US Active

Antiviral treatment

US11433080B2 · kind B2 · utility

1Cited by

1References

23Claims

0Family size

Assignee

CEBINA GMBH · AT

Inventors

Eszter Nagy · Wien, AT
Gabor Nagy · Redmond, US
Valeria SZIJARTO · Wien, AT
Robert Konrat · Wien, AT

Key dates

Filing date	Dec 27, 2021
Grant date	Sep 6, 2022
Priority date	—
Expiry date	Dec 27, 2041

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 μg per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.